ClassID:

96715

C07K5/0821 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Sub-classes:
Recent Application in this class:
#1
20260091126
2026-04-02

AMINO ACID-MODIFIED LIPIDS FOR RNA DELIVERY

#2
20260062443
2026-03-05

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#3
20260000728
2026-01-01

PEPTIDE HAVING ACE INHIBITORY ACTIVITY AND COMPOSITION CONTAINING THE SAME

#4
20250382328
2025-12-18

TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS

#5
20250367304
2025-12-04

FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS

#6
20250333440
2025-10-30

Azole Tripeptides as Vasodilators

#7
20250059231
2025-02-20

Protease inhibitors

#8
20240392319
2024-11-28

TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME

#9
20240294569
2024-09-05

MODULATORS OF SORTILIN ACTIVITY

#10
20240228535
2024-07-11

PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

#11
20240132542
2024-04-25

TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS

#12
20240116989
2024-04-11

Process for the preparation of cyclic depsipeptides

#13
20240092829
2024-03-21

PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME

#14
20240002896
2024-01-04

PEPTIDE TAG AND TAGGED PROTEIN CONTAINING SAME

#15
20230340018
2023-10-26

MPRO CYSTEINE PROTEASE INHIBITORS

#16
20230312644
2023-10-05

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#17
20230234985
2023-07-27

USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES

#18
20230174985
2023-06-08

MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS

#19
20230159622
2023-05-25

COLLAGEN MIMICS

#20
20230133667
2023-05-04

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#21
20230100707
2023-03-30

MELANOMA THERAPEUTICS

#22
20220411468
2022-12-29

Peptide macrocycles against

#23
20220324914
2022-10-13

Modified peptide nucleic acid compositions

#24
20220267699
2022-08-25

PEPTIDE ACETALS FOR STABILISING ENZYMES

#25
20220190232
2022-06-16

Piezoelectric peptide-based materials and piezoelectric devices containing same

#26
20220169676
2022-06-02

INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES

#27
20220112238
2022-04-14

MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS

#28
20220090141
2022-03-24

Transfection complexes and methods of using the same

#29
20220009965
2022-01-13

PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITY

#30
20220002347
2022-01-06

Process for the preparation of cyclic depsipeptides

#31
20210404450
2021-12-30

Humidity-responsive tripeptide crystal

#32
20210379190
2021-12-09

FAP-activated proteasome inhibitors for treating solid tumors

#33
20210355163
2021-11-18

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#34
20210261612
2021-08-26

LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT

#35
20210253634
2021-08-19

PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

#36
20210198316
2021-07-01

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#37
20210147478
2021-05-20

Inhibitors of blood coagulation factor XIII

#38
20210094983
2021-04-01

Modified peptides for use in treating neurodegenerative disorders

#39
20210038678
2021-02-11

Compositions comprising cyclic peptides derived from an A-beta peptide

#40
20200392181
2020-12-17

PEPTIDE COMPOSITIONS AND RELATED METHODS

#41
20200369723
2020-11-26

LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT

#42
20200354402
2020-11-12

PEPTIDE COMPOSITIONS AND RELATED METHODS

#43
20200347097
2020-11-05

Process for the preparation of cyclic depsipeptides

#44
20200323994
2020-10-15

FAP-activated proteasome inhibitors for treating solid tumors

#45
20200323947
2020-10-15

Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

#46
20200283502
2020-09-10

POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR

#47
20200283477
2020-09-10

Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

#48
20200253852
2020-08-13

Pro-pigmenting peptides

#49
20200231626
2020-07-23

Peptide inhibitors of tight junction permeability

#50
20200207809
2020-07-02

Tripeptide epoxy ketone protease inhibitors

#51
20200172572
2020-06-04

PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

#52
20200109167
2020-04-09

Small molecule DCN1 inhibitors and therapeutic methods using the same

#53
20200087343
2020-03-19

Epoxyketone compounds for enzyme inhibition

#54
20200055895
2020-02-20

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#55
20200024328
2020-01-23

Collagen mimics

#56
20200024309
2020-01-23

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#57
20190389904
2019-12-26

MALT1 inhibitors and uses thereof

#58
20190322700
2019-10-24

Inhibitors of transglutaminases

#59
20190300569
2019-10-03

Peptide macrocycles against

#60
20190263858
2019-08-29

Compounds

#61
20190177372
2019-06-13

Process for the preparation of cyclic depsipeptides

#62
20190151401
2019-05-23

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

#63
20190142723
2019-05-16

Pro-pigmenting peptides

#64
20190127419
2019-05-02

Neuropeptide S receptor (NPSR) agonists

#65
20190120849
2019-04-25

Water-soluble peptide fluorescence material

#66
20190062372
2019-02-28

METHODS OF TREATING DEPRESSION AND OTHER RELATED DISEASES

#67
20190054181
2019-02-21

FAP-activated proteasome inhibitors for treating solid tumors

#68
20180371016
2018-12-27

Trifluoromethylpropanamide derivatives as HTRA1 inhibitors

#69
20180362578
2018-12-20

Peptide macrocycles against Acinetobacter baumannii

#70
20180340188
2018-11-29

Transfection complexes and methods of using the same

#71
20180305404
2018-10-25

NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE

#72
20180273585
2018-09-27

Medical Use

#73
20180264126
2018-09-20

Compound with effects of thrombolysis, free radical scavenging and thrombus-targeting

#74
20180251489
2018-09-06

MALT1 inhibitors and uses thereof

#75
20180236112
2018-08-23

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

#76
20180186833
2018-07-05

Selective cysteine protease inhibitors and uses thereof

#77
20180147291
2018-05-31

Prodrugs of peptide epoxy ketone protease inhibitors

#78
20180134750
2018-05-17

Inhibition of gliadin peptides

#79
20180134748
2018-05-17

Process for preparing compounds having triple activities of thrombolysis, antithrombosis, and radical scavenging

#80
20180127464
2018-05-10

NOVEL EPHA4 INHIBITORS TARGETING ITS LIGAND BINDING DOMAIN

#81
20180094026
2018-04-05

Methods of treating depression and other related diseases

#82
20180066016
2018-03-08

Method of using pharmaceutical compositions comprising selective peptide-based agonists of melanocortin 1 receptor

#83
20180066015
2018-03-08

Inhibitors of growth factor activation enzymes

#84
20180057528
2018-03-01

Indoline compounds as granzyme B inhibitors

#85
20180052170
2018-02-22

Water-soluble peptide fluorescence material

#86
20180030115
2018-02-01

Collagen mimics

#87
20170260231
2017-09-14

Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof

#88
20170260230
2017-09-14

Compounds for enzyme inhibition

#89
20170233437
2017-08-17

Peptide macrocycles against acinetobacter baumannii

#90
20170196933
2017-07-13

Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

#91
20170183375
2017-06-29

Use of a tetraphenylborate (TPB) salt for the separation of biomolecules

#92
20170174722
2017-06-22

LLP2A-bisphosphonate conjugates for osteoporosis treatment

#93
20170158734
2017-06-08

Epoxyketone compounds for enzyme inhibition

#94
20170121367
2017-05-04

Agonists of neurotrophin receptors and their use as medicaments

#95
20170121366
2017-05-04

Dipeptides as inhibitors of human immunoproteasomes

#96
20170096451
2017-04-06

INHIBITION OF GLIADIN PEPTIDES

#97
20170071844
2017-03-16

Pro-pigmenting peptides

#98
20170049912
2017-02-23

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

#99
20170015707
2017-01-19

Covalent granzyme B inhibitors

#100
20170008924
2017-01-12

PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME

#101
20170008922
2017-01-12

Branched chain-containing aromatic compound

#102
20160368946
2016-12-22

Tripeptide epoxy ketone protease inhibitors

#103
20160346401
2016-12-01

FAP-activated proteasome inhibitors for treating solid tumors

#104
20160340387
2016-11-24

Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide

#105
20160263234
2016-09-15

Prodrugs of peptide epoxy ketone protease inhibitors

#106
20160243249
2016-08-25

HCV protease inhibitors and uses thereof

#107
20160229867
2016-08-11

Thieno[2,3-e]indole derivatives as new antitumor agents

#108
20160222077
2016-08-04

Composition comprising peptide derived from adiponectin

#109
20160221927
2016-08-04

Intermediates for macrocyclic compounds

#110
20160115198
2016-04-28

METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF

#111
20160083425
2016-03-24

Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels

#112
20160083423
2016-03-24

Compounds having triple activities of thrombolysis, antithrombosis, and radical scavenging, synthesis, and use thereof

#113
20160083422
2016-03-24

Indoline compounds as granzyme B inhibitors

#114
20160045607
2016-02-18

Estrogen-related receptor alpha based protac compounds and associated methods of use

#115
20160031934
2016-02-04

Dipeptide and tripeptide epoxy ketone protease inhibitors

#116
20160030590
2016-02-04

Vectors for delivery of agents across biological membranes

#117
20160016993
2016-01-21

Process for preparing tubulysins

#118
20160009713
2016-01-14

Prodrugs of heteraromatic compounds

#119
20160002292
2016-01-07

Methods of treating depression and other related diseases

#120
20150353601
2015-12-10

Compounds for enzyme inhibition

#121
20150322109
2015-11-12

Process for producing Sovaprevir

#122
20150299251
2015-10-22

Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor

#123
20150297667
2015-10-22

Pharmaceutical compositions comprising selective peptide-based agonists of melanocortin 1 receptor

#124
20150274776
2015-10-01

Pro-pigmenting peptides

#125
20150203537
2015-07-23

INHIBITION OF GLIADIN PEPTIDES

#126
20150175657
2015-06-25

HCV protease inhibitors and uses thereof

#127
20150175656
2015-06-25

Crystalline tripeptide epoxy ketone protease inhibitors

#128
20150133368
2015-05-14

Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses

#129
20150119330
2015-04-30

Substrates and inhibitors of prolyl oligopeptidase and methods of use

#130
20150011730
2015-01-08

Cyclin based inhibitors of CDK2 and CDK4

#131
20150010541
2015-01-08

Macrocyclic compounds useful as inhibitors of histone deacetylases

#132
20150005239
2015-01-01

Agonists of neurotrophin receptors and their use as medicaments

#133
20140371135
2014-12-18

High purity lipopeptides

#134
20140341804
2014-11-20

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

#135
20140322306
2014-10-30

Method of treating endometriosis

#136
20140309174
2014-10-16

HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER

#137
20140296136
2014-10-02

HCV NS3 protease inhibitors

#138
20140275480
2014-09-18

Processes for Producing sovaprevir

#139
20140255300
2014-09-11

FAP-activated proteasome inhibitors for treating solid tumors

#140
20140243501
2014-08-28

Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments

#141
20140243255
2014-08-28

Treatments for

#142
20140206021
2014-07-24

Prion protein ligands and methods of use

#143
20140100354
2014-04-10

PEPTOID COMPOSITIONS AND METHODS OF USING THE SAME

#144
20140100168
2014-04-10

Prodrugs of peptide epoxy ketone protease inhibitors

#145
20140100154
2014-04-10

Prodrugs of peptide epoxy ketone protease inhibitors

#146
20140094420
2014-04-03

Hydrogel-forming material

#147
20140051641
2014-02-20

Compounds for enzyme inhibition

#148
20140050737
2014-02-20

Compounds for enzyme inhibition

#149
20140038903
2014-02-06

Selective cysteine protease inhibitors and uses thereof

#150
20140031297
2014-01-30

Compounds for enzyme inhibition

#151
20140024804
2014-01-23

Crystalline tripeptide epoxy ketone protease inhibitors

#152
20140018300
2014-01-16

Neuroprotective and neurorestorative methods and compositions

#153
20130338062
2013-12-19

HCV protease inhibitors and uses thereof

#154
20130316954
2013-11-28

Methods of treating depression and other related diseases

#155
20130310323
2013-11-21

Methods of treating depression and other related diseases

#156
20130288975
2013-10-31

Methods of treating depression and other related diseases

#157
20130280760
2013-10-24

High purity lipopeptides

#158
20130274439
2013-10-17

Antiviral compounds

#159
20130130968
2013-05-23

COMPOUNDS FOR ENZYME INHIBITION

#160
20130116183
2013-05-09

Peptides that inhibit angiotensin converting enzyme and peptides with antioxidant activity purified from ovotransferrin and methods of producing and using the same

#161
20130095122
2013-04-18

Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein

#162
20130053577
2013-02-28

Antiviral compounds

#163
20130053303
2013-02-28

Compounds for enzyme inhibition

#164
20130041008
2013-02-14

Compounds for enzyme inhibition

#165
20130035297
2013-02-07

Compounds for enzyme inhibition

#166
20130017991
2013-01-17

HCV protease inhibitors and uses thereof

#167
20130005662
2013-01-03

Methods of treating depression and other related diseases

#168
20120322722
2012-12-20

Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use

#169
20120309938
2012-12-06

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#170
20120295852
2012-11-22

Methods of treating depression and other related diseases

#171
20120226072
2012-09-06

PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS

#172
20120226067
2012-09-06

PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS

#173
20120226066
2012-09-06

PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS

#174
20120190866
2012-07-26

Antiviral compounds

#175
20120190614
2012-07-26

HCV protease inhibitors and uses thereof

#176
20120165566
2012-06-28

PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS

#177
20120165319
2012-06-28

INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME

#178
20120149062
2012-06-14

High purity lipopeptides

#179
20120135921
2012-05-31

Tripeptide boronic acid or boronic ester, preparative method and use thereof

#180
20120108520
2012-05-03

Method of treating tumors

#181
20120088903
2012-04-12

Crystalline tripeptide epoxy ketone protease inhibitors

#182
20120088762
2012-04-12

Compounds for enzyme inhibition

#183
20120077855
2012-03-29

Crystalline tripeptide epoxy ketone protease inhibitors

#184
20120059149
2012-03-08

Branched chain-containing aromatic compound

#185
20120052094
2012-03-01

Agonists of neurotrophin receptors and their use as medicaments

#186
20120027781
2012-02-02

Neuroprotective and neurorestorative method and compositions

#187
20120015866
2012-01-19

Prodrugs of heteraromatic compounds

#188
20120004720
2012-01-05

G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES

#189
20110319347
2011-12-29

ANTIOXIDANT AGENT

#190
20110275562
2011-11-10

Inhibition of gliadin peptides

#191
20110257077
2011-10-20

Compounds and compositions as channel activating protease inhibitors

#192
20110245459
2011-10-06

Processes for intermediates for macrocyclic compounds

#193
20110237785
2011-09-29

Spatially-defined macrocyclic compounds useful for drug discovery

#194
20110230419
2011-09-22

IAP BINDING COMPOUNDS

#195
20110207658
2011-08-25

High purity lipopeptides

#196
20110195408
2011-08-11

Labeling dye for detecting biomolecule, labeling kit, and method for detecting biomolecule

#197
20110191867
2011-08-04

PEPTIDE VACCINE FOR INFLUENZA VIRUS

#198
20110178069
2011-07-21

Inhibitors of interleukin-1β converting enzyme

#199
20110098446
2011-04-28

Use of a tetraphenylborate (TPB) salt for the separation of biomolecules

#200
20110092671
2011-04-21

Peptide manufacturing process

#201
20110052528
2011-03-03

Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage

#202
20110040087
2011-02-17

PEPTIDE TURN MIMETICS

#203
20100331489
2010-12-30

Branched water-soluble polymers and their conjugates

#204
20100280229
2010-11-04

POLYPEPTIDE

#205
20100279955
2010-11-04

Lipid tripeptide-based hydrogelator and hydrogel

#206
20100267621
2010-10-21

Antimicrobial compounds and formulations

#207
20100266677
2010-10-21

Nucleic acid binding compounds and methods of use

#208
20100261914
2010-10-14

IAP BINDING COMPOUNDS

#209
20100240903
2010-09-23

CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS

#210
20100240598
2010-09-23

PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES

#211
20100240066
2010-09-23

Compounds and methods for modulating cadherin-mediated processes

#212
20100234564
2010-09-16

Methods and intermediates for chemical synthesis of polypeptides and proteins

#213
20100233190
2010-09-16

Targeted polymeric prodrugs containing multifunctional linkers

#214
20100227825
2010-09-09

PEPTIDES AND PEPTIDE MIMETICS TO TREAT CANCER

#215
20100204160
2010-08-12

SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF

#216
20100159006
2010-06-24

Antimicrobial peptides

#217
20100144649
2010-06-10

Compounds for enzyme inhibition

#218
20100144648
2010-06-10

Compounds for enzyme inhibition

#219
20100080770
2010-04-01

Hepatitis C Virus Inhibitors

#220
20100074920
2010-03-25

PEPTIDE VACCINE FOR INFLUENZA VIRUS

#221
20100069294
2010-03-18

HCV protease inhibitors and uses thereof

#222
20100068150
2010-03-18

Selective Caspase Inhibitors

#223
20100063095
2010-03-11

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#224
20100041674
2010-02-18

HCV protease inhibitors and uses thereof

#225
20100041591
2010-02-18

HCV protease inhibitors and uses thereof

#226
20100035291
2010-02-11

METHOD FOR DEGRADING PEPTIDES, METHOD FOR ANALYZING PEPTIDES, DEVICE FOR DEGRADING PEPTIDES AND DEVICE FOR ANALYZING PEPTIDES

#227
20090325940
2009-12-31

Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof

#228
20090298781
2009-12-03

COMPOUNDS FOR THE INHIBITION OF APOPTOSIS

#229
20090263472
2009-10-22

ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES

#230
20090258891
2009-10-15

Macrocyclic compounds as antiviral agents

#231
20090258834
2009-10-15

Plasma protein-binding ligands

#232
20090257978
2009-10-15

Antiviral compounds

#233
20090253896
2009-10-08

Selective substrates for matrix metalloproteinases

#234
20090240027
2009-09-24

Intermediates for macrocyclic compounds

#235
20090215025
2009-08-27

SMALL PEPTIDIC AND PEPTIDO-MIMETIC AFFINITY LIGANDS FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS

#236
20090203698
2009-08-13

Compounds for enzyme inhibition

#237
20090186869
2009-07-23

Antiviral compounds

#238
20090137835
2009-05-28

Processes for intermediates for macrocyclic compounds

#239
20090137817
2009-05-28

Spatially-defined macrocyclic compounds useful for drug discovery

#240
20090137458
2009-05-28

Methods and compositions for increasing skin remodeling

#241
20090111731
2009-04-30

Topical application agents against mimic and age-related wrinkles

#242
20090088390
2009-04-02

POLYPEPTIDE

#243
20090076094
2009-03-19

Antibacterial compounds

#244
20090075869
2009-03-19

HCV NS3 protease inhibitors

#245
20090036653
2009-02-05

Methods for the directed expansion of epitopes for use as antibody ligands

#246
20090005881
2009-01-01

Composite material useful as biomaterial and its preparation

#247
20080287371
2008-11-20

MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX

#248
20080274978
2008-11-06

Peptides that antagonize FPR class receptor mediated signaling

#249
20080268474
2008-10-30

Prion protein ligands and methods of use

#250
20080267916
2008-10-30

Cyclic P3 tripeptide hepatitis C serine protease inhibitors

#251
20080249028
2008-10-09

Thyrotropin-Releasing Hormone Analogs and Method of Use

#252
20080176806
2008-07-24

Therapeutic uses of tri-, tetra-, penta-, and polypeptides

#253
20080171698
2008-07-17

Anti-hypertensive molecules and process for preparation thereof

#254
20080160501
2008-07-03

Plasma protein-binding ligands

#255
20080146504
2008-06-19

Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability

#256
20080108820
2008-05-08

Hemiasterlin Derivatives and Uses Thereof

#257
20080051434
2008-02-28

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#258
20080039449
2008-02-14

Inhibitors of interleukin-1β converting enzyme

#259
20070293465
2007-12-20

Compounds for enzyme inhibition

#260
20070275906
2007-11-29

Compounds and compositions as channel activating protease inhibitors

#261
20070275897
2007-11-29

Collagen mimics

#262
20070207946
2007-09-06

Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels

#263
20070191280
2007-08-16

High purity lipopeptides

#264
20070161640
2007-07-12

Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders

#265
20070155670
2007-07-05

Pyrrolidine melanocortin-specific compounds

#266
20070111930
2007-05-17

PROCESS FOR PREPARING VAPREOTIDE

#267
20070105786
2007-05-10

Compounds for enzyme inhibition

#268
20070066539
2007-03-22

Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof

#269
20070032437
2007-02-08

IAP binding compounds

#270
20070032405
2007-02-08

Branched water-soluble polymers and their conjugates

#271
20070020257
2007-01-25

Polypeptide

#272
20060293372
2006-12-28

Beta-sheet mimetics and methods relating to the use thereof

#273
20060293247
2006-12-28

TRH-degrading ectoenzyme inhibitors

#274
20060276408
2006-12-07

β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins

#275
20060223759
2006-10-05

Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof

#276
20060217295
2006-09-28

Neuroprotective macrocyclic compounds and methods for their use

#277
20060205669
2006-09-14

G-type peptides and other agents to ameliorate atherosclerosis and other pathologies

#278
20060183691
2006-08-17

Anti-hypertensive molecules and process for preparation thereof

#279
20060166893
2006-07-27

2-hydroxytetrahydrofuran derivatives and use thereof as medicaments

#280
20060154872
2006-07-13

Hemiasterlin derivatives and uses thereof

#281
20060141531
2006-06-29

Ultra-high specificity fluorescent labeling

#282
20060128632
2006-06-15

Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

#283
20060106059
2006-05-18

Melanocortin receptor ligands

#284
20060052311
2006-03-09

Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (IAP)

#285
20060019945
2006-01-26

Granzyme b inhibitors

#286
20060014676
2006-01-19

Cyclic peptides for treatment for cachexia

#287
20060014194
2006-01-19

Cyclic peptides for treatment of cachexia

#288
20060009395
2006-01-12

Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm

#289
20050267150
2005-12-01

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

#290
20050261172
2005-11-24

Agents and methods for promoting bone growth

#291
20050239870
2005-10-27

Hemiasterlin derivatives and uses thereof

#292
20050239829
2005-10-27

Piperidine compounds

#293
20050222045
2005-10-06

Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments

#294
20050215484
2005-09-29

Di-, tri-, and tetra-peptides having antiangiogenic activity

#295
20050215423
2005-09-29

Process of removing transition metals

#296
20050192269
2005-09-01

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

#297
20050181989
2005-08-18

Selective substrates for matrix metalloproteinases

#298
20050143436
2005-06-30

Inhibitors of interleukin-1beta converting enzyme

#299
20050137127
2005-06-23

Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists

#300
20050107308
2005-05-19

Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels